We found that a single infusion of 750 mg/m2 or perhaps even 375 mg/m2 could be used for treating children with autoimmune diseases while retaining similar treatment effect as observed by CD19+ lymphocyte reduction within 6 months (Figure 4); meanwhile the lowering rituximab dose would yield reduced treatment costs and possibly reduced infection risk. The gene discussed is CD19; the disease is autoimmune disease.